Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 9/20 | 0.55 |
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16816242 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16815686 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL20745566 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL20513851 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16815495 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL14215338 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16815687 | 0.75 | MAPT (0.52) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16815276 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16815718 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL20745064 | 0.75 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| CN-111818916-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3668502-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035927-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SMN1; SMN2 605/4885KMT2A 1365/4885MAPT 4497/4885 |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SMN1; SMN2 605/4885KMT2A 1365/4885MAPT 4497/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SMN1; SMN2 605/4885KMT2A 1365/4885MAPT 4497/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SMN1; SMN2 605/4885KMT2A 1365/4885MAPT 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.